NasdaqGS - Nasdaq Real Time Price USD

Halozyme Therapeutics, Inc. (HALO)

Compare
62.49 -1.35 (-2.12%)
As of 10:53 AM EDT. Market Open.
Loading Chart for HALO
DELL
  • Previous Close 63.85
  • Open 63.65
  • Bid 62.39 x 300
  • Ask 62.60 x 100
  • Day's Range 62.44 - 64.18
  • 52 Week Range 32.83 - 65.53
  • Volume 243,289
  • Avg. Volume 1,384,448
  • Market Cap (intraday) 7.917B
  • Beta (5Y Monthly) 1.28
  • PE Ratio (TTM) 24.22
  • EPS (TTM) 2.58
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 59.89

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

halozyme.com

373

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HALO

View More

Research Reports: HALO

View More

Performance Overview: HALO

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HALO
69.09%
S&P 500
16.64%

1-Year Return

HALO
45.95%
S&P 500
23.20%

3-Year Return

HALO
45.98%
S&P 500
22.62%

5-Year Return

HALO
278.30%
S&P 500
90.11%

Compare To: HALO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HALO

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    8.09B

  • Enterprise Value

    9.06B

  • Trailing P/E

    24.75

  • Forward P/E

    19.68

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.57

  • Price/Book (mrq)

    27.95

  • Enterprise Value/Revenue

    10.38

  • Enterprise Value/EBITDA

    17.43

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    38.62%

  • Return on Assets (ttm)

    13.38%

  • Return on Equity (ttm)

    153.16%

  • Revenue (ttm)

    873.3M

  • Net Income Avi to Common (ttm)

    337.29M

  • Diluted EPS (ttm)

    2.58

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    529.03M

  • Total Debt/Equity (mrq)

    529.73%

  • Levered Free Cash Flow (ttm)

    335.21M

Research Analysis: HALO

View More

Company Insights: HALO

People Also Watch